Juvenile Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology in Sardinia, Insular Italy

Abstract

Background Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and disabling immunomediated radiculoneuropathy. Its worldwide epidemiology is heterogeneous and, in adults, CIDP prevalence varies from 0.6 to 9 cases per 100,000 population. Juvenile CIDP (jCIDP) is even rarer, with age-specific prevalence rates varying from 0.23 to 1.26 owing to different diagnostic criteria (American Academy of Neurology [AAN] and European Federation of Neurological Societies/Peripheral Nerve Society [EFNS/PNS]), different age grouping or, genuine differences.

Objectives We assessed jCIDP incidence and prevalence in Sardinia, an area at very-high risk for autoimmune diseases, using comparable methods.

Design The study area was the northern Sardinia, insular Italy, with 491,571 inhabitants and a pediatric population (0–18 years) of 79,086 individuals.

Results On prevalence day (December 31, 2019) the total crude, age-specific prevalence rate were 6.32 per 100,000 according with AAN criteria, 7.58 per 100,000 population with European Neuromuscular Center (ENMC) criteria, and 8.85 per 100,000 population with both 2006 and 2010 EFNS/PNS criteria. Crude mean incidence rate were 0.42 per 100,000 per year with AAN criteria, 0.50 per 100,000 per year with ENMC criteria, and 0.59 per 100,000 per year using 2006 and 2010 EFNS/PNS criteria. Of the eight patients, six had typical CIDP, one had multifocal-acquired demyelinating sensory and motor neuropathy (MADSAM), and one chronic immune sensory polyradiculopathy (CISP). Patient's disability was generally mild. Clinical course was progressive, monophasic, or relapsing.

Conclusion jCIDP prevalence and incidence rates in Sardinia were criteria-dependent, the lowest obtained when using AAN criteria, the highest using the EFNS/PNS. Nonetheless, even with the exclusion of the “possible” category, by using comparable methodology, prevalence rates in Sardinia are considerably higher than the range reported in all previous jCIDP studies.

Keywords

CIDP - epidemiology - prevalence - incidence - Sardinia - diagnostic criteria

Publication History

Received: 09 March 2020

Accepted: 01 July 2020

Article published online:
27 October 2020

• References

• 1 Doneddu PE, Cocito D, Manganelli F. et al; Italian CIDP Database study group. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry 2019; 90 (02) 125-132
• 2 Hattori N, Misu K, Koike H. et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2001; 184 (01) 57-63
• 3 Nevo Y, Topaloglu H. 88th ENMC international workshop: childhood chronic inflammatory demyelinating polyneuropathy (including revised diagnostic criteria), Naarden, The Netherlands, December 8-10, 2000. Neuromuscul Disord 2002; 12 (02) 195-200
• 4 Potulska-Chromik A, Ryniewicz B, Aragon-Gawinska K. et al. Are electrophysiological criteria useful in distinguishing childhood demyelinating neuropathies?. J Peripher Nerv Syst 2016; 21 (01) 22-26
• 5 Iijima M, Koike H, Hattori N. et al; Refractory Peripheral Neuropathy Study Group of Japan. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 2008; 79 (09) 1040-1043
• 6 Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol 2014; 21 (01) 28-33
• 7 McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999; 46 (06) 910-913
• 8 Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009; 39 (04) 432-438
• 9 Chiò A, Cocito D, Bottacchi E. et al; PARCIDP. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 2007; 78 (12) 1349-1353
• 10 Dell'Avvento S, Sotgiu MA, Manca S, Sotgiu G, Sotgiu S. Epidemiology of multiple sclerosis in the pediatric population of Sardinia, Italy. Eur J Pediatr 2016; 175 (01) 19-29
• 11 Graham RC, Hughes RA. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry 2006; 77 (08) 973-976
• 12 Ad Hoc Subcommittee of the American Academy of Neurology AIDS Taskforce. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an ad hoc subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41 (05) 617-618
• 13 Hughes RA, Bouche P, Cornblath DR. et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006; 13 (04) 326-332
• 14 Van den Bergh PY, Hadden RD, Bouche P. et al; European Federation of Neurological Societies, Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol 2010; 17 (03) 356-363
• 15 Carrera-García L, Natera-de Benito D, Lleixà C. et al. Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child. Neurol Neuroimmunol Neuroinflamm 2019; 6 (05) e602